Profound Medical Corp. saw its stock jump following new trial results revealing that its TULSA procedure delivers better quality-of-life outcomes compared to traditional robotic surgery. The CAPTAIN trial highlighted that TULSA not only preserves penile length but also leads to improved patient experiences after treatment.
The study's findings have boosted investor confidence in Profound Medical, reflecting optimism about the wider adoption of TULSA in prostate cancer therapy. This advancement signals a potential shift in how surgical interventions are evaluated, emphasizing long-term quality of life alongside clinical effectiveness.
